Table 5.

IR per 100,000 person-years, rate ratio, and rate difference of each study outcome for single use of moderate- to high-potency topical corticosteroids and the untreated population

Study outcome	Topical corticosteroidsa		Untreated populationb		Matched IRR (95% CI)	Matched IRD (95% CI)
	Number of events	IR	Number of events	IR
Children, 0–<18 years	(195,631 person-years)		(189,798 person-years)
MM	2	1.0	1	0.5	1.93 (0.16–23.03)	0.5 (–1.2, 2.2)
NMSC	1	0.5	1	0.5	0.94 (0.06–15.66)	0.0 (–1.5, 1.4)
Any lymphoma	4	2.0	0	0.0	NE	2.1 (0.0, 4.1)c
NHL	1	0.5	0	0.0	NE	0.5 (–0.5, 1.6)c
HL	3	1.5	0	0.0	NE	1.6 (–0.2, 3.3)c
CTCL	0	0.0	0	0.0	NE	NE
Adults, ≥18 years	(789,435 person-years)		(717,457 person-years)
MM	263	33.3	276	38.5	0.87 (0.74–1.03)	–4.9 (–10.9, 1.2)
NMSC	2,166	274.4	1,652	230.3	1.19 (1.11–1.27)	43.4 (27.4, 59.4)
Any lymphoma	196	24.8	119	16.6	1.49 (1.19–1.87)	8.2 (3.6, 12.8)
NHL	138	17.5	105	14.6	1.19 (0.93–1.53)	2.8 (–1.2, 6.9)
HL	34	4.3	12	1.7	2.55 (1.32–4.90)	2.6 (0.9, 4.4)
CTCL	24	3.0	2	0.3	10.66 (2.60–43.75)	2.8 (1.5, 4.1)

Notes: Topical corticosteroids refer to moderate- to high-potency topical corticosteroids.

^aCohort of users of moderate- to high-potency topical corticosteroids identified as the comparative cohort for topical tacrolimus.

^bUntreated cohort matched to users of moderate- to high-potency topical corticosteroids on year of birth, sex, primary care general practice/region (except in Denmark), and calendar year of cohort entry.

^cCrude IRD.

Abbreviations: CI, confidence interval; CTCL, cutaneous T-cell lymphoma; HL, Hodgkin lymphoma; IR, incidence rate; IRD, IR difference; IRR, IR ratio; MM, malignant melanoma including in situ tumors; NE, not estimable; NHL, non-Hodgkin lymphoma; NMSC, non-melanoma skin cancer including in situ tumors.